Rigel(US:RIGL)2022-05-03 20:08Financial Performance - For the three months ended March 31, 2022, net product sales of TAVALISSE were $16.2 million, a 31% increase compared to the same period in 2021[102]. - Total revenues for the three months ended March 31, 2022, were $16.735 million, a decrease of $64.283 million compared to $81.018 million in the same period in 2021[171]. - Net product sales of TAVALISSE increased by $3.8 million or 31% to $16.197 million in Q1 2022, driven by sales force expansion and increased engagement[171]. - Contract revenues from collaborations fell to $0.538 million in Q1 2022 from $65.642 million in Q1 2021, primarily due to the loss of significant revenue from Lilly[172]. - Research and development expenses decreased to $15.474 million in Q1 2022 from $16.826 million in Q1 2021, mainly due to reduced personnel-related costs[176]. - Selling, general and administrative expenses increased to $27.401 million in Q1 2022 from $22.121 million in Q1 2021, driven by higher personnel-related costs and commercial activities[188]. - Interest income increased to $21,000 in Q1 2022 from $1,000 in Q1 2021, while interest expense rose to $1.205 million from $485,000[191]. - Net cash used in operating activities for Q1 2022 was $(25.6) million, compared to $(20.0) million in Q1 2021, mainly due to higher cash outflows from changes in assets and liabilities[201]. - Net cash provided by investing activities in Q1 2022 was $22.6 million, compared to $7.5 million in Q1 2021, driven by net maturities of short-term investments[202]. - Net cash provided by financing activities in Q1 2022 was $8.8 million, primarily from a $10.0 million term loan financing and $0.9 million from stock options[203]. - As of March 31, 2022, the company had approximately $107.5 million in cash, down from $125.0 million as of December 31, 2021[200]. - The company anticipates that existing capital resources will support operations for at least the next 12 months, but future funding needs may require additional financing[204]. Clinical Trials and Product Development - Fostamatinib is being studied in a Phase 3 trial for the treatment of wAIHA, with topline data expected to be reported in mid-2022[105]. - The company completed enrollment for the Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients, targeting 308 patients, with 268 enrolled as of May 2, 2022[108]. - A post-hoc analysis showed a 78% response rate for TAVALISSE as a second-line therapy in chronic ITP patients[104]. - Fostamatinib significantly increased platelet counts in chronic ITP patients, with 18% achieving a stable platelet response compared to 0% in the placebo group in the first Phase 3 study (p=0.0261) [123]. - The second Phase 3 study reported a response rate of 16% in the treatment group versus 4% in the placebo group, although the difference was not statistically significant [123]. - Fostamatinib received Orphan Drug designation from the FDA in August 2015 for the treatment of ITP, and was approved by the FDA in April 2018 for adult patients with insufficient response to previous treatments [124]. - The European Commission granted marketing authorization for fostamatinib in January 2020, leading to a non-refundable milestone payment of $20 million [135]. - Kissei initiated a Phase 3 trial in Japan for fostamatinib in chronic ITP, reporting positive topline results in December 2021, with a stable platelet response significantly higher than placebo [139]. - In the Phase 2 trial for wAIHA, 44% of evaluable patients achieved the primary efficacy endpoint of hemoglobin levels greater than 10 g/dL by week 24 [143]. - The FORWARD study for fostamatinib, targeting approximately 90 patients with wAIHA, completed enrollment in November 2021, with topline data expected in mid-2022[145]. - Fostamatinib received Fast Track designation from the FDA for wAIHA treatment in January 2021, following its Orphan Drug designation in January 2018[146]. - A Phase 3 trial for fostamatinib in hospitalized COVID-19 patients, funded by a $16.5 million grant from the US Department of Defense, targets 308 patients and has updated its primary endpoint to the number of days on oxygen through day 29[148]. - The NIH/NHLBI-sponsored Phase 2 trial of fostamatinib met its primary safety endpoint, reducing the incidence of Serious Adverse Events (SAEs) by 50% compared to placebo[149]. - The Phase 2 trial reported three SAEs in the fostamatinib group versus six in the placebo group, with a p-value of 0.23[150]. - Fostamatinib was selected for the NIH ACTIV-4 trial, focusing on hospitalized COVID-19 patients, with primary outcomes including oxygen-free days through day 28[153]. - The Imperial College of London Phase 2 trial did not meet the criteria for continuation, although no safety concerns were identified[154]. - R289, an oral IRAK1/4 inhibitor, received FDA clearance for a Phase 1b study in low-risk myelodysplastic syndromes (LR MDS) in January 2022[162]. - The company has an exclusive agreement with BerGenBio for the AXL inhibitor BGB324, currently in Phase 2 trials for COVID-19 and oncology indications[163]. Strategic Partnerships and Agreements - The global strategic partnership with Lilly includes an upfront cash payment of $125 million and potential milestone payments totaling $585 million for both non-CNS and CNS disease products[112]. - The company is responsible for 20% of development costs for R552 in the US, Europe, and Japan, up to a maximum funding commitment of $65 million through April 1, 2024[111]. - The company has entered into various license agreements for fostamatinib, including an upfront payment of $30 million from Grifols and $33 million from Kissei, with potential milestone payments totaling $297.5 million and $147 million respectively [135][137]. - Under the global exclusive license agreement with Lilly, the company is responsible for funding development costs for R552 up to $65.0 million through April 1, 2024, with $4.9 million billed by Lilly as of March 31, 2022[218]. - The agreement with AZ for a proprietary JAK inhibitor was terminated in December 2021, returning full rights to the company[168]. Operational Adjustments and COVID-19 Impact - The company anticipates an increase in in-person engagements with healthcare providers as COVID-19 cases decline[103]. - The impact of COVID-19 has led to reduced patient-doctor interactions, negatively affecting product sales growth[117]. - The company has implemented a hybrid work schedule to ensure safety while continuing business operations[116]. - The company expects to continue to monitor and adapt to the evolving effects of the COVID-19 pandemic on its business[118]. - The company plans to expand its commercial activities further in 2022, despite uncertainties related to the COVID-19 pandemic[190]. Financial Obligations and Risks - The company has a principal term loan outstanding of $30.0 million with MidCap, with an additional $30.0 million available until March 31, 2023[209]. - Future contingent payments from collaboration agreements could exceed $500.0 million, excluding potential payments from Lilly, based on achieving specified milestones[206]. - The company has a contractual commitment related to facilities lease amounting to $8.8 million, expiring in January 2023[219]. - Company has a credit facility with MidCap, with an outstanding principal amount of $30.0 million as of March 31, 2022, and future interest payments estimated at $4.0 million[220]. - Company is subject to claims related to patent protection and other litigations, requiring assessment of potential losses and reserves[221]. - No material changes to market risk disclosures related to investment activities during the three months ended March 31, 2022[223].